Sino-American Pharmaceutical Professionals Association-New England (sapa-ne)
Download 122.5 Kb.
|
- Navigate this page:
- A Molecular Level Systems Engineering
- Abstract
- A Career Transition from Science to Business Development – from Big Pharma to Biotech
- The Changing Environment for Pharmaceutical
AbstractTechnology commercialization requires a combination of critical factors that contribute to the success of a new company. This presentation will analyze the importance of attitudes, management teams, ownership distribution, IP management, investors and investment strategy, location and speed to market. Biography Roland Franke is the CEO of Natural Pharmaceuticals, Inc., a pharmaceutical company focussed on the GMP production of very difficult to manufacture Active Pharmaceutical Ingredient (API). The first product of the company is paclitaxel (API), a very successful and potent anti-cancer drug through a novel semi-synthetic pathway. Dr. Franke has been with NPI for 3 1/2 years. Before founding NPI he has worked in the pharmaceutical consulting practice of Booz Allen & Hamilton for 3 years. Dr. Franke has a B.S. and M.S. in synthetic organic chemistry from Freiburg University in Germany. He did his Ph.D. work with Prof. Khorana at MIT and worked subsequently for three years on a gene therapy project as a Howard Houghes Associate at the Rockefeller University. He has also a M.B.A. from the Sloan School of Management with a focus on corporate finance and entrepreneurship.
AbstractIn recent times, powerful new technologies have been developed and applied to the pharmaceutical drug discovery process. These include structure-based design, high-throughput screening, combinatorial chemistry, structural design, selection and ADME/toxicity prediction tools, genomics, proteomics, chip-based analytics and bioinformatics. These technologies have brought significant advances to the discovery process, but major new bottlenecks have emerged and important unmet needs remain. The application of these high-throughput principles to the discovery, development, scale-up and production of chemistry-based products is discussed. A molecular level systems engineering approach, targeted toward underlying commonalities of this very large and heterogeneous market is outlined. Biography Joseph Hogan, Ph.D. is Founder, President and Chief Executive Officer of Alveus Systems, Inc. This unique company is focused on integrating combinatorial and information sciences to produce a revolutionary new convergent high-throughput discovery and development approach to chemistry-based products and processes. Prior to forming Alveus Systems, Dr. Hogan was the Founder of ArQule, Inc. From 1993-99 he served as ArQule’s Chairman, Senior Vice President of R&D and Chief Scientific Officer and led the company’s pioneering programs in the development of combinatorial chemistry, automation and informatics technologies for the parallel solution phase synthesis and characterization of congeneric arrays of molecules for accelerating pharmaceutical drug discovery. Dr. Hogan has over 25 years of management experience in the design, development and manufacturing of sophisticated chemistries, processes and products. After serving as Vice President Chemical Products Research, Development and Engineering at the Waters Division of Millipore, he founded and was President of Molecular Recognition, Inc. and Applied Modular Chemistries, Inc., an MRI predecessor. Earlier he spent 14 years at Polaroid Corp. in a series of scientific management positions, most recently as Manager of the Chemical Synthesis Laboratory.
AbstractA start-up company within a large pharmaceutical company can provide unique opportunities to experience an entrepreneurial environment for any scientist. While working as a chemist at Parke-Davis in 1995, I had the opportunity to serve as a Vice president of Technical Development for a spin-out company, Diversomer Technologies. When efforts to finance the company were unsuccessful, I decided to make a career transition into business development. I will describe my transition into business development over the last five years in two different biotechnology companies and the opportunities – and challenges – that exist for other scientists. Biography Dr. DeWitt joined ArQule in February 2000 as Director of Business Development. She has held several scientific and senior management positions at pharmaceutical, biotechnology, and agricultural chemical companies including: FMC Agricultural Chemical Group (1986-1988), Parke-Davis Pharmaceutical Research (1988-1995), Diversomer Technologies, a combinatorial chemistry start-up company incubated at Parke-Davis (1995-1997), and Orchid BioSciences (1997-2000). Dr. DeWitt earned her B.A. in Chemistry from Cornell University and her Ph.D. in Synthetic Organic Chemistry from Duke University. Dr. DeWitt is internationally recognized for her pioneering efforts in Combinatorial Chemistry dating from 1992. She has been the recipient of several awards including the Michigan Leading Edge Technologies Award (1993), Pioneer in Laboratory Robotics Award (1995), and Association for Laboratory Automation Outstanding Service Award (1997). She is an active member of the American Chemical Society (ACS) and the Association of Laboratory Automation (ALA) and has served as a Committee Member for the National Research Council and co-chair for the ACS ProSpectives Conferences. She has edited a book entitled, “A Practical Guide to Combinatorial Chemistry”, published more 35 manuscripts, is the inventor on more than 30 patents, and has taught numerous short courses.
Directory: conference conference -> Tilte : a critical examination of the police relations with bbc conference -> Eavesdropping on a virtuous circle Richard Whately and the Oriel Noetics. Elena Pasquini Douglas uwa business School conference -> Simulation and Prediction of Storm Surges, Waves, and Morphological Changes due to Tropical Cyclones by Using a pc-based Integrated Coastal Process Model conference -> Panel 0511 Disability and Difference I: Post-War Journeys through Disability conference -> Do remittances have a flip side? A general equilibrium analysis of remittances, labor supply responses and policy options for Jamaica* Maurizio Bussolo and Denis Medvedev conference -> Conference approval process made easy for acm in cooperation conferences conference -> Proceedings of gt2009 asme turbo Expo 2009: Power for Land, Sea and Air Orlando, Florida, USA gt2009-59981 dynamics of premixed h2/CH4 flames under near blowoff conditions conference -> South Korea’s Economic Future: Industrial Policy, or Economic Democracy? conference -> Asset rotator Cuff Rehabilitation Course Faculty Dr. Spero Karas conference -> Acm word Template for sig site Download 122.5 Kb. Share with your friends:
|
